Incidence (per 1000 person-years) of hematologic disorders (anemia or hematologic malignancy) among ADT, RT, and RP groups.

Incidence (per 1000 person-years) of hematologic disorders (anemia or hematologic malignancy) among ADT, RT, and RP groups.</p

Propensity score-matched Cox regression analysis for the association between the duration of ADT use and hematologic disorders.

Propensity score-matched Cox regression analysis for the association between the duration of ADT use and hematologic disorders.</p

Overall survival (OS) stratified by variants of urothelial carcinoma (VUC) or pure urothelial carcinoma (PUC).

<p>Overall survival (OS) stratified by variants of urothelial carcinoma (VUC) or pure urothelial carcinoma (PUC).</p

Demographic characteristics of prostate cancer patients according to use of androgen deprivation therapy, radiotherapy, and radical prostatectomy.

Demographic characteristics of prostate cancer patients according to use of androgen deprivation therapy, radiotherapy, and radical prostatectomy.</p

Clinical characteristics of 206 patients with advanced urothelial carcinoma.

<p>Abbreviations: PUC, pure urothelial carcinoma; VUC, variants of urothelial carcinoma; CCr, clearance of creatinine; ECOG, Eastern Cooperative Oncology Group</p><p>Clinical characteristics of 206 patients with advanced urothelial carcinoma.</p

Progression-free survival (PFS) stratified by variants of urothelial carcinoma (VUC) or pure urothelial carcinoma (PUC).

<p>Progression-free survival (PFS) stratified by variants of urothelial carcinoma (VUC) or pure urothelial carcinoma (PUC).</p

Kaplan-Meier curves according to ADT, RT, and RP use for the cumulative probabilities of remaining free of hematologic disorders in general(a); remaining anemia-free (b); and remaining hematologic malignancy-free (c) in the propensity score–matched cohort.

ADT = androgen deprivation therapy; RT = radiotherapy; RP = radical prostatectomy.</p

Distribution of histopathological variants.

<p>Distribution of histopathological variants.</p

ADT by type and the risk of subsequent hematologic disorders.

ADT by type and the risk of subsequent hematologic disorders.</p

Study flowchart of cohort selection.

Study flowchart of cohort selection.</p